Jonathan Hopper - Feb 20, 2024 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Stock symbol
VCEL
Transactions as of
Feb 20, 2024
Transactions value $
-$153,747
Form type
4
Date filed
2/22/2024, 04:06 PM
Previous filing
Feb 13, 2024
Next filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $0 +3K +5.56% $0.00 57K Feb 20, 2024 Direct F1, F2
transaction VCEL Common Stock Tax liability -$68.3K -1.38K -2.42% $49.50 55.6K Feb 20, 2024 Direct F2, F3
transaction VCEL Common Stock Options Exercise $0 +2.33K +4.18% $0.00 57.9K Feb 20, 2024 Direct F2, F4
transaction VCEL Common Stock Tax liability -$48.8K -985 -1.7% $49.50 56.9K Feb 20, 2024 Direct F2, F3
transaction VCEL Common Stock Options Exercise $0 +1.75K +3.07% $0.00 58.7K Feb 20, 2024 Direct F2, F5
transaction VCEL Common Stock Tax liability -$36.7K -742 -1.26% $49.50 58K Feb 20, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Restricted Stock Unit Options Exercise +3K +50% 9K Feb 20, 2024 Common Stock 3K Direct F1, F6, F7, F8
transaction VCEL Restricted Stock Unit Options Exercise +2.33K +100% 4.65K Feb 20, 2024 Common Stock 2.33K Direct F4, F6, F7, F8
transaction VCEL Restricted Stock Unit Options Exercise +1.75K 1.75K Feb 20, 2024 Common Stock 1.75K Direct F5, F6, F7, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest in annual installments on February 17, 2025, February 17, 2026, and February 17, 2027, respectively.
F2 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F4 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022. The remaining RSUs will vest in annual installments on February 18, 2025, and February 18, 2026, respectively.
F5 The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 19, 2021. The remaining RSUs will vest on February 19, 2025.
F6 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F7 No expiration date for this type of award.
F8 The Fair Market Value of the vested derivative securities is $49.50 per share.